Purine nucleoside phosphorylase (PNP) enzyme catalyzes dephosphorylation of guanosine, deoxyguanosine, inosine and deoxyinosine. [1] [2] [3] [4] [5] [6] In PNP deficiency, these metabolites accumulate, with marked increases especially in the thymus, where high cell turnover takes place. Early in life, patients with PNP deficiency develop a combined immunodeficiency particularly affecting T cell function, while B cell function may be preserved longer. The disorder accounts for about 4% of all patients with severe combined immunodeficiency (SCID) and has a heterogeneous clinical course. [1] [2] [3] [4] [5] [6] The initial symptoms are usually recurrent infections becoming obvious from the second half of infancy, especially severe varicella, encephalitis, or recurrent pneumonias leading to chronic pulmonary disease. Hemolytic anemia, thrombocytopenic purpura and lupus have been reported in some patients, as has the development of lymphoma and other malignancies. In some cases, graft-versushost disease has occurred due to transfusion of nonirradiated blood cells. Vaccinations, even BCG, have how-ever, been reported to be tolerated well in several cases. 1 The diagnosis can be suspected by low levels of uric acid in the serum and especially the urine. It is confirmed by determination of purines in body fluids by HLPC. 2, 5 Concomitant with the immunological deficiency, most patients show neurological symptoms. These are heterogeneous, and include spastic paresis, tremor, ataxia, and developmental delay. In some cases, neurological problems become apparent before severe infections develop, usually showing a pattern of slow progression. The neurological impairment is probably due to intracerebral accumulation of toxic purines. However, at present, studies on the neuropathophysiology of PNP deficiency are rare. [1] [2] [3] Due to recurrent infections, the course of the disease is usually fatal in the first and sometimes the second decade of life.
The PNP gene has been cloned and mapped to chromosome 14q13. Various mutations have been identified so far, including exon skipping, missense, and frameshift mutations. [7] [8] [9] [10] The metabolic abnormality and immunodeficiency have been corrected by bone marrow transplantation (BMT) in several patients. [11] [12] [13] [14] However, no reversal of the neurological symptoms was observed. Gene therapy represents an interesting prospect for the future, with promising results from several in vitro approaches, 15, 16 but the technique has not been applied clinically to date.
Here, we describe a patient who was diagnosed with PNP deficiency when she presented with neurological symptoms, and who was successfully transplanted from her HLA-identical brother after conditioning with busulfan and fludarabine.
Case report

Patient history
The female patient was born as the third child of healthy, unrelated parents; there was no history of hereditary diseases or early deaths in the family. The pregnancy was uneventful, but birth at term (4250 g, 54 cm) was complicated by dystokia of the right shoulder, leading to transient paresis of the upper plexus. From the sixth month of life, muscular hypotonia of the trunk became apparent. At 1 year The methodology of the assay has been described. 2, 5 of age, the patient was able to turn, but failed to sit or crawl. When brought into the sitting position she tended to fall to either side or backwards. Mild ataxia was found in both arms and legs, with mild spastic muscular hypertonia. Spontaneous motion was reduced. There was no apparent impairment of psychosocial development, or interest in her surroundings. The patient had received all regular vaccinations including live vaccination against BCG and polio without complications. At the age of 22 months, the girl had not experienced any life-threatening infections. However, a chickenpox infection at the age of 20 months, had been relatively protracted despite administration of aciclovir.
Laboratory investigations now showed mild anemia with a hemoglobin of 97 g/l and lymphopenia (500/l). The blood count was otherwise normal, as were electrolytes, creatinine, BUN, AST, ALT, ␥GT, LDH, lipase, amylase, blood coagulation parameters, vitamin status and thyroid hormone status. Plasma uric acid was very low at 3 mol/l. Screening for antenatal infections (TORCH) was negative. Amino acids and organic acids in the urine were normal. In the CSF, protein, glucose, lactate, neurotransmitters, and amino acids, including glycine, were normal. Uric acid excretion in the urine was very low (43.9 mmol/mol creatinin) with normal xanthine and hypoxanthine values. Inosin, guanosin, 2Ј-desoxyguanosin and 2Ј-desoxyinosin in the urine were all highly elevated pointing to PNP deficiency. PNP activity in erythrocytes was zero (Table  1) . Thus, absolute PNP deficiency was confirmed. Both the parents and two siblings of the patient were heterozygous for the disease (Table 1) . Immunological investigations demonstrated a severe T cellular immunodeficiency in the child (Table 2) , with normal serum immunoglobulin levels at the time of presentation. Neurophysiological examinations including EEG, nerve conduction velocity and craniospinal magnetic resonance tomography were normal. The ophthalmological status was normal. On ultrasound examination, the thymus appeared non-homogeneous with many irregularities on ultrasound, and the retrosternal part of the thymus was very thin (size: 31 × 11 × 29 mm). Ultrasonographic examination of all other organs were normal. Other technical investigations which included cardiologic examination, X-ray of the chest, and EEG were normal.
The older brother was found to be HLA-identical, and the patient was referred at the age of 25 months for BMT.
Status before BMT
On admission, the patient was in good clinical condition, with no infections, normal-sized lymph nodes and visible tonsils. Marked muscular hypotonia of the trunk with kyphosis and hypertonia and hyperreflexia of the limbs was present; sitting was possible, but there was no crawling or walking. The patient spoke single words only, but seemed to understand whole sentences. After fully informed consent of both parents, BMT was performed using an experimental conditioning regimen with busulfan and fludarabine.
Bone marrow transplantation
Conditioning prior to BMT consisted of busulfan 5 mg/kg p.o. in four divided doses daily for 4 days (day −13 to day −10; total dose 20 mg/kg) and fludarabine 40 mg/m 2 in one dose daily for 5 days (day −8 to day −4; total dose 200 mg/m 2 ). On day 0, 420 ml bone marrow was infused from the 5-year-old HLA-identical and blood group-compatible brother, containing 5.7 × 10 8 nucleated cells per kg. GVHD prophylaxis consisted of cyclosporin A starting on day −1 with serum levels between 50 and 100 g/l which was tapered from day +35 to day +49. Toxicity from conditioning consisted of alopecia and mucositis (1st degree). Hematological reconstitution occurred at an appropiate time, with neutrophils Ͼ1000/l on day +26 and reticulocytes Ͼ20% on day +45. Thrombocyte transfusion was required only once (day +6) and the platelets remained stable Ͼ20 000/l afterwards. Engraftment was proven on day +95 by blood group typing and by identification of normal PNP activity in blood mononuclear cells.
The patient remained free of infectious complications and there were no signs of GVHD at any time. Full chimerism was confirmed several times by blood group analysis.
Until now (19 months post BMT) the patient remains free of infection, and no delayed transplantation-related complications have occurred.
Immunological investigations
Immunological findings before and after BMT are summarized in Table 2 .
As is characteristic of PNP deficiency, there was severe impairment of T and B cellular functions before BMT with low numbers of both T and B cells. Absolute immunoglobulin levels, however, were normal. On day +95 after BMT, T cells were found to be normal in number and subset distribution and showed regular proliferation upon in vitro stimulation. After vaccination against diphtheria and tetanus, the patient developed appropriate specific antibodies.
Neurological outcome
During the early phase after BMT, the neurological status of the patient remained unchanged. She continued to show spastic hypertonia of her limbs with hypotonia of the trunk; she could sit, but was unable to stand or to walk and spoke only a few words. She received intensive physiotherapy. At the age of 36 months, she started to speak in complete sentences and she started to walk freely at the age of 42 months. At present, at the age of 50 months, there are no signs of intellectual deficits. However, there is still significant spasticity, especially of legs, and hypotonia of the trunk.
Discussion
Bone marrow or stem cell transplantation is the only curative therapy for PNP deficiency. Since the disorder has a poor prognosis with a high rate of death in infancy and childhood, this is the treatment of choice, if an HLA-identical donor is available. About 50 patients have been identified with PNP deficiency since the disorder was first reported in 1975. 4 Of 33 patients reviewed in 1991, seven underwent treatment by BMT, of whom two survived. 1 Of the remainder diagnosed since, one died before a suitable donor could be found (personal communication, HAS). The others have had successful BMTs, two from unrelated matched donors. 11, 12 These findings illustrate the potentially lethal nature of the disorder and the importance of early diagnosis and treatment.
In all patients reported who were successfully transplanted, 10-13 a myeloablative conditioning regimen was used, usually with a combination of busulfan and cyclophosphamide. Fludarabine has so far only been used in combination with busulfan and cyclophosphamide. 11 In some of the patients, anti-lymphocyte-globulin was given.
To reduce toxicity, especially the risk of veno-occlusive disease (VOD), we gave an experimental conditioning regimen with busulfan and fludarabine only, after fully informed consent from the parents. Severe VOD is not uncommon following conditioning with a combination of the two alkylating agents busulfan and cyclophosphamide, which may interact to potentiate hepatotoxicity. 17 Fludarabine has
Bone Marrow Transplantation been used for conditioning in BMT since 1996. The data published so far indicate relatively low toxicity with busulfan/fludarabine. 18 Slavin et al 19 reported a high incidence of mild VOD with busulfan (8 mg/kg) and fludarabine (180 mg/m 2 ). However, the proportion of severe VOD in these patients, most of whom were heavily pretreated, was about the same as compared to regimens using busulfan/cyclophosphamide.
The busulfan/fludarabine conditioning regimen used in our patient was tolerated well, with low toxicity and engraftment taking place promptly. We were able to withdraw GVHD prophylaxis early, and there were no signs of GVHD. The patient developed full immunological functions with normal T cell numbers and in vitro functions over time, and normal responses to vaccines. At present, with full chimerism proven, she can be regarded as cured of her immunodeficiency. Therefore, we believe, that in PNP deficiency patients with an HLA-identical sibling donor, conditioning using busulfan and fludarabine might be sufficient, resulting in reduced toxicity.
Data on the neurological outcome of PNP patients successfully treated by BMT are limited. According to one early review, neurological abnormalities usually persist. 16 A more recent case transplanted at 4 years of age with spastic diplegia showed no reversal of the paresis 4 years later, but no further neurological deterioration was observed, and new motor skills and developmental milestones were gained. 12 Our patient, likewise, although still symptomatic with neurological impairment -muscular hypertonia of the limbs, ataxia, and trunk hypotonia -has gained neuromotor functions after BMT instead of falling back developmentally.
Based on this experience in a single patient, we conclude that allogeneic BMT using a low-toxicity conditioning regimen combining busulfan and fludarabine may offer the possibility of correcting the immunodeficiency and preventing further neurological deterioration.
